ALS, Motor Neuron Disease, and Related Disorders: A Personal Approach to Diagnosis and Management

ABSTRACT

Motor neuron disease, from diagnostic criteria, laboratory evaluation, communication with patients and their families, and the approach to long-term management represents a daunting challenge for many neurologists. Contained herein is a selective and biased discussion of several common dilemmas and questions that reflect recurring themes in the evaluation and management of patients with suspected motor neuron disease. The answers to these questions represent the author's opinions and are colored by personal experience, pearls graciously given to me by other experts in the field, and selected studies from the neuromuscular literature.

KEYWORDS

Management of motor neuron disease - ALS - multifocal motor neuropathy - Kennedy's disease

REFERENCES

• 1 Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial ``Clinical Limits of Amyotrophic Lateral Sclerosis'' Workshop Contributors. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis.  J Neurol Sci . 1994;  124(suppl) 96-107
• 2 Ross M A, Miller R G, Berchert L. Toward earlier diagnosis of ALS: revised criteria.  Neurology . 1998;  50 768-772
• 3 Brooks B R, Miller R G, Swash M, Munsat T. El Escorial Revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. In: World Federation of Neurology Subcommittee of Motor Neuron Disease Website: www.wfnals.org/ Articles/elescorial1998.htm, 1998
• 4 Dabby R, Lange D J, Rowland L P. Inclusion body myositis mimicking motor neuron disease.  Arch Neurol . 2001;  58 1253-1256
• 5 Fischer D, Wullner U, Klockgether T, Schroder R, Wilhelm K. Cervical spondylotic myelopathy and Kennedy syndrome mimicking amyotrophic lateral sclerosis.  J Neurol, Neurosurg & Psych . 2001;  71 414
• 6 Bouche P, Moulonguet A, Younes-Chennoufi A B. Multifocal motor neuropathy with conduction block: a study of 24 patients.  J Neurol Neurosurg Psychiatr . 1995;  59 38-44
• 7 Pestronk A. Multifocal motor neuropathy: diagnosis and treatment.  Neurology . 1998;  51 S22-24
• 8 Kennedy W R, Alter M, Sung J H. Progressive proximal spinal and bulbar muscular atrophy of late onset. A sex-linked recessive trait.  Neurology . 1968;  18 671-680
• 9 Harding A E, Thomas P K, Baraitser M. X-linked recessive bulbospinal neuronopathy: a report of ten cases.  J Neurol Neurosurg Psychiatry . 1982;  45 1012-1019
• 10 Rosen D R, Siddique T, Patterson D. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis.  Nature . 1993;  362 59-62
• 11 Juneja T, Pericak-Vance M A, Laing N G, Dave S, Siddique T. Prognosis in familial amyotrophic lateral sclerosis: progression and survival in patients with glu100gly and ala4val mutations in Cu,Zn superoxide dismutase.  Neurology . 1997;  48 55-57
• 12 Berger M M, Kopp N, Vital C, Redel B, Aymard M, Lina B. Detection and cellular localization of enterovirus RNA sequences in spinal cord of patients with ALS.  Neurology . 2000;  54 20-25
• 13 Walker M P, Schlaberg R, Hays A, Bowser R, Lipkin W I. Absence of echovirus sequences in brain and spinal cord of amyotrophic lateral sclerosis patients.  Annals of Neurology . 2001;  49 249-253
• 14 Pleconaril: a broad spectrum anti-picornaviral agent.  Adv Exp Med Biol   1999;  458 69-76
• 15 Moulignier A, Moulonguet A, Pialoux G, Rozenbaum W. Reversible ALS-like disorder in HIV infection.  Neurology . 2001;  57 995-1001
• 16 MacGowan D JL, Scelsa M D, Waldron M. An ALS-like syndrome with new HIV infection and complete response to anti-retroviral therapy.  Neurology . 2001;  57 1094-1097
• 17 Almer G, Guegan C, Teismann P. Increased expression of the pro-inflammatory enzyme cyclooxygenase-2 in amyotrophic lateral sclerosis.  Ann Neurol . 2001;  49 176-185
• 18 Yasojima K, Tourtellotte W W, McGeer E G, McGeer P L. Marked increase in cyclo-oxygenase-2 in ALS spinal cord: Implications for therapy.  Neurology . 2001;  57 952-956
• 19 Drachman D B, Rothstein J D. Inhibition of cyclooxygenase-2 protects motor neurons in an organotypic model of amyotrophic lateral sclerosis.  Ann Neurol . 2000;  48 792-795
• 20 Miller R, Mitchell J, Moore D. Riluzole for amyotrophic lateral sclerosis/motor neuron disease (Cochrane Review). Oxford: Cochrane Library; 2000
• 21 Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group.  N Engl J Med . 1994;  330 585-591
• 22 Lacomblez L, Bensimon G, Leigh P N. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II.  Lancet . 1996;  347 1425-1431
• 23 Tarnopolsky M, Martin J. Creatine monohydrate increases strength in patients with neuromuscular disease.  Neurology . 1999;  52 854-857
• 24 Klivenyi P, Ferrante J, Matthews R T. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis.  Nature Med . 1999;  5 347-350
• 25 Miller R G, Rosenberg J A, Gelinas D F. Practice parameter: the care of the patient with amyotrophic lateral sclerosis (an evidence-based review). Report of the Quality Standards Subcommittee of the AAN.  Neurology . 1999;  52 1311-1323